Clinical Data announced it will provide genomic testing services to the pain research community based on Algynomics’ proprietary panel of genetic markers. This panel is designed to examine the genetic basis or underpinnings of human pain sensitivity, pain conditions, and responses to existing and new pharmacological agents used to treat pain, inflammation and mood disorders. The genetic panel is the result of more than ten years of rigorous pain research performed at the University of North Carolina’s Center for Neurosensory Disorders located within UNC’s School of Dentistry, and which has been licensed to Algynomics for commercialization.

Robert Bondaryk, PhD, Senior Vice President and General Manager of Cogenics, commented, “We are pleased to reach this agreement and look forward to working closely with Algynomics to bring this unique research tool in the area of chronic and acute pain to market. This collaboration fits well with Clinical Data’s model of commercializing proprietary offerings in pharmacogenomics for our clients in research and clinical settings and brings unique value to our pharma, biotech and academic clients doing research and drug development in all of the therapeutic categories where pain management is a significant challenge.”

Algynomics was only started in 2005. Its website offers little information about the company’s location or scientists, except to say that the company licensed intellectual property from the University of North Carolina at Chapel Hill. The company does estimate pain to be a $125 billion market.